Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Incyte announced that positive Phase 3 results from the frontMIND study of tafasitamab in first-line diffuse large b-cell lymphoma will be presented at the 2026 ASCO Annual Meeting. Management stated the data support global regulatory submissions, with the full results set to be shared during an oral presentation on May 30.
Key figures
- Drug Name
- tafasitamab (Monjuvi®/Minjuvi®)
- Phase Of Trial
- Phase 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.